Q2 2026 Grail Inc Earnings Call Transcript
Key Points
- GRAIL Inc (GRAL) reported strong Q2 2026 results with total revenue of $44.7 million, up 26% year-over-year, driven by a 35% increase in Galleri test volumes to over 61,000 tests.
- The company's clinical evidence base is unmatched, with data from the 140,000-participant NHS Galleri trial and 35,000-participant Pathfinder 2 study demonstrating a false positive rate of less than 0.5% and a 4 to 6.5 times increase in cancer detection when added to standard of care.
- GRAIL Inc (GRAL) completed a $110 million strategic investment from Samsung, which will support international expansion into Asian markets including South Korea, Japan, and Singapore.
- The company's expanded field sales and medical teams are now fully onboarded and trained, with initial feedback from physicians since the ASCO conference being very positive.
- GRAIL Inc (GRAL) ended Q2 2026 with a strong cash position of $861.6 million, providing financial flexibility to advance key priorities including FDA approval and reimbursement.
- The company announced a new collaboration with Priority Health to expand employer group coverage for the Galleri test, building on existing payer partnerships.
- The primary endpoint of the NHS Galleri trial—a combined reduction of stage III and IV cancers—was not met, which could raise questions about the test's ultimate clinical utility.
- GRAIL Inc (GRAL) expects the FDA to convene an advisory committee in the fall, adding uncertainty to the approval timeline, which is currently anticipated for early 2027.
- The company faces increasing competition from other multi-cancer early detection (MCED) tests that are launching based on case-control data, causing confusion in the market and potentially impacting pricing.
- Average selling price (ASP) decreased in Q2 2026 due to planned lower employer pricing and expansion of digital health volume, which could pressure future revenue growth.
- Adjusted EBITDA loss widened by 15% year-over-year to negative $90.3 million, reflecting increased investment in sales force expansion and other growth initiatives.
- The Illumina royalty obligation will resume in Q4 2026, which will negatively impact gross margins and profitability going forward.
Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2026 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that this conference call is being recorded. GRAIL Investor Relations, please begin.
Thank you, and thank you all for joining us today. On the call are Josh Offman, our Chief Executive Officer Erin Frieden, Chief Financial Officer Sir Harpal Kumar, Chief Scientific Officer and President, Global Clinical and Medical Affairs and Andy Partridge, Chief Growth Officer. I'll remind you that we'll be making forward-looking statements based on current expectations. It's our intent that all statements other than statements of historical fact, including statements regarding our anticipated financial results and commercial activity, will be covered by the Safe Harbor provisions for forward-looking statements under federal securities laws. Forward-looking statements are subject to risks and uncertainties.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
